Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer

The compound discovered exhibited high selectivity among 215 kinases and significantly suppressed the proliferation and metastasis of prostate cancer cells in vitro.